gms | German Medical Science

33. Internationale Konferenz für Elektrokardiographie

Internationale Konferenz für Elektrokardiographie

Treatment Of Arrhythmias In Patients With Unstable Angina. The Role Of Statins

Meeting Abstract

Suche in Medline nach

  • corresponding author presenting/speaker V. Chupina - Donetsk State Medical university, Donetsk, Ukraine
  • N. Vatutin - Donetsk State Medical university, Donetsk, Ukraine
  • L. Kardashevska - Donetsk State Medical university, Donetsk, Ukraine

33rd International Congress on Electrocardiology. Cologne, 28.06.-01.07.2006. Düsseldorf, Köln: German Medical Science; 2007. Doc06ice126

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/ice2006/06ice126.shtml

Veröffentlicht: 8. Februar 2007

© 2007 Chupina et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Question: Statins have demonstrated their benefit effects on the mortality rate in patients with an unstable angina (UA), independently on the blood lipid profile. It is well known that the main cause of cardiovascular death is the fatal arrhythmias. The aim of the present study was to evaluate the influence of statins on atrial fibrillation (AF) and ventricular arrhythmias (VA) in patients with UA and to determine the relationship between the “anti-arrhythmic” and the anti-inflammatory activities of statins.

Method used: 60 patients with UA and without history of AF or VA were enrolled to the study (39 m, mean age 58,6±3,6 y.). The patients were divided in two groups: group I received standard therapy of US (n=28); group II were treated also with a statin (simvastatin, 20mg/day) (n=32). Standard therapy included enoxaparin, b-blockers, aspirin, ACE inhibitors and nitrates. High-sensitivity C-reactive protein (hsCRP) levels were measured at an admission, and on the 60th day of the follow-up period. Holter-ECG-monitoring was performed at the same terms to assess the arrhythmias onset.

Results: Baseline the hsCRP levels were increased in both groups (12,67±0,26 mg/L in group I; 12,74±0,28 mg/L in group II). On the 60th day of the follow-up the hsCRP levels were significantly higher in I group (1,82±0,25mg/L vs 0,65±0,28 mg/L, p<0,05). On an admission day the AF episodes rate was comparable in both groups (21,43% vs 21,88%, p>0,05). 60 days of US-treatment decreased the AF incidence, more considerable in the 2nd group (10,71% vs 6,25%, p<0,05). The VA rate at baseline was 67,86% in group I, and 65,63% in group II, p>0,05. On the 60th day VA were significantly more often observed in the I group (32,14% vs 18,75%, p<0,05).

Conclusions: these data demonstrated, that statins could decrease the hsCRP levels and the incidence of AF and VA in patients with UA. Anti-arrhythmic properties of statin might be realized through their anti-inflammatory effects.